| 4.68 Delayed Data As of Nov 21 |  +0.23 / +5.17%Today’s Change | 4.01 Today|||52-Week Range 12.60 | -7.33% Year-to-Date |
| Options Traders Expect Huge Moves in Arbutus (ABUS) Stock Nov 21 / Zacks.com - Paid Partner Content |
| Previous close | 4.45 |
| Today’s open | 4.52 |
| Day’s range | 4.38 - 4.73 |
| Volume | 171,660 |
| Average volume (3 months) | 428,857 |
| Market cap | $246.9M |
| Earnings growth (last year) | +78.45% |
| Earnings growth (this year) | +29.17% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | +617.64% |
| P/E ratio | NM |
| Price/Sales | 25.83 |
| Price/Book | 1.85 |
| Today’s change | Today’s % change | |
|---|---|---|
| ATHXAthersys Inc | +0.11 | +5.85% |
| BDSIBioDelivery Sciences... | +0.03 | +0.83% |
| ADROAduro Biotech Inc | -0.23 | -7.54% |
| CNCEConcert Pharmaceutic... | +0.18 | +1.45% |
| Next reporting date | March 7, 2019 |
| EPS forecast (this quarter) | -$0.40 |
| Annual revenue (last year) | $10.7M |
| Annual profit (last year) | -$84.4M |
| Net profit margin | -788.91% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Mark J. Murray |
Chief Financial Officer David C. Hastings |
Corporate headquarters Burnaby, British Columbia |
